Why Moderna Was So Volatile on Thursday
Moderna (NASDAQ: MRNA) was a roller-coaster stock on Thursday, at one point trading 3% higher, then as much as 6% lower, before settling in for a 1.3% loss at the end of the day.
A business update and several fresh pieces of news, released on the company's annual "R&D Day," left the market wondering whether such developments were collectively positive or negative for the high-profile biotech.
Moderna said that its mRNA-1273 coronavirus vaccine candidate could win emergency use authorization (EUA) from the Food and Drug Administration as soon as the end of this year. If that happens, it said, it will be prepared to produce millions of doses of the vaccine. Moderna added that it has enrolled 25,296 participants for mRNA-1273's current phase 3 study, well within reach of its 30,000 goal.
Source Fool.com
